ID   NCI-H226b
SY   H226b; H226B; H226-B
DR   Cosmic; 2645022
DR   Wikidata; Q95993364
RX   PubMed=8528963;
RX   PubMed=9498829;
RX   PubMed=28676216;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1544 ! NCI-H226
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 8
RX   PubMed=8528963;
RA   Cai D.-W., Mukhopadhyay T., Roth J.A.;
RT   "Suppression of lung cancer cell growth by ribozyme-mediated
RT   modification of p53 pre-mRNA.";
RL   Cancer Gene Ther. 2:199-205(1995).
RX   PubMed=9498829; DOI=10.1007/s004320050127;
RA   Perdomo J.A., Naomoto Y., Haisa M., Fujiwara T., Hamada M.,
RA   Yasuoka Y., Tanaka N.;
RT   "In vivo influence of p53 status on proliferation and
RT   chemoradiosensitivity in non-small-cell lung cancer.";
RL   J. Cancer Res. Clin. Oncol. 124:10-18(1998).
RX   PubMed=28676216; DOI=10.1016/j.lungcan.2017.05.017;
RA   Kobayashi-Watanabe N., Sato A., Watanabe T., Abe T., Nakashima C.,
RA   Sueoka E., Kimura S., Sueoka-Aragane N.;
RT   "Functional analysis of discoidin domain receptor 2 mutation and
RT   expression in squamous cell lung cancer.";
RL   Lung Cancer 110:35-41(2017).